Are you prepared to impact patient care?

“Are you prepared to impact patient care?” That was the challenge Dennis Helling, PharmD, FCCP, FASHP, made to School of Pharmacy students at the Marguerite C. Holden Annual Lecture held April 15.

“We have known for 30 years pharmacists can make a difference in a variety of disease states,” said Dr. Helling, executive director of Pharmacy Operations and Therapeutics for Kaiser Permanente in Denver and an adjunct professor in the University of Colorado School of Pharmacy.

Preparing for a pharmacy career was the subject of his lecture held in Denison Auditorium. Marguerite Holden, a CU graduate and long-time benefactor of the school, was present at the lecture she supports.

Dr. Helling explained that a successful pharmacy career today requires teamwork, good communications skills, building relationships with nurses and physicians, and cultivating a mentor relationship with a faculty member or pharmacist.

To show how a pharmacy career has evolved over the past decade, he gave examples of Kaiser’s pharmacy department, where pharmacists operate in specialized roles providing enhanced patient healthcare, education, and counseling.

Dr. Helling’s staff of 700 pharmacists, clinical pharmacy specialists, technicians and administrative support collaborators with physicians to offer clinical pharmacy expertise in such areas as primary care, management of diabetes, coronary artery disease, travel medicine, infectious diseases, cardiology and rheumatology.

Pharmacists function as part of a multidisciplinary team consulting in drug therapies; developing prescribing guidelines with physicians; patient medication counseling and education; and other patient-focused services to optimize drug therapy outcomes.

All clinical pharmacy specialists at Kaiser have a PharmD degree and a specialty faculty residency or fellowship training, and within their first three years of employment are required to receive board certification of their specialty.

His advice to the students in the audience was to get into a residency program, which 25 percent of the School of Pharmacy students are already planning to do.

“It needs to be more than just passing exams,” he admonished the students. “It’s crucial for your career track.”

Primary care clinical pharmacy specialists at Kaiser are located in the heart of the internal medicine and family practice units, with a ratio of one clinical pharmacy specialist for every 15,000 adult patients or one for every seven to eight adult primary care physicians. Clinical pharmacy specialists work in other areas: drug information, mental health, oncology, counseling, asthma, organ transplant, kidney disease, patient palliative care as well as home-based palliative care.

“For every clinical pharmacy specialist I hire in primary care, we save in drug costs twice the amount of their salary and benefits,” he said. The Pharmacy Automated Refill Center (PARC), by using robotic technology to process some 6,000 prescriptions a day, frees up pharmacists so they have more time for patient care activities. PARC utilizes bar codes, radio frequency transmitters and drug imaging to process 40 percent of the total prescription volume. Pharmacists perform clinical screening and provide final checks on prescriptions filled through the PARC system.

Two examples of areas overseen by clinical pharmacy specialists in Kaiser’s centralized services are anticoagulation and cardiac risk where results show a significant decrease in complications and deaths. Twenty pharmacists manage 6,500 active anticoagulation patients and 20 pharmacists manage 10,500 cardiac patients in the Denver/Boulder area.

Among the anticoagulation patients there was a 39 percent reduction in clotting complications resulting in 25 lives saved each year, while 193 deaths from secondary heart attacks are avoided annually in cardiac patients.

Transition of care is the focus of the Clinical Pharmacy Call Center. Whether it’s a new patient to Kaiser or a patient going home from the hospital or a skilled nursing facility, a team of clinical pharmacists handle upwards of 1,200 patient calls a day at the center. Pharmacists contact patients to sort out medication duplications, interacting drugs and inappropriate over-the-counter substances before the patient sees a Kaiser physician. Pharmacists and physicians at the Call Center work closely together in assisting their patients.

“Pharmacists organize all that information and send it to the primary care physician for the first visit,” he said, “so the physician can concentrate on the patient and not have to spend time sorting out medications often time from physicians and pharmacies outside of Kaiser.”

A pilot study revealed alarming results for patients who were simply discharged to go home from a skilled nursing facility and then became confused about their medications. As part of the study, a pharmacist called a third of the patients discharged from skilled nursing facilities within 24-48 hours of being home to review their medication instructions.

Comparing these to the other patients, the study showed that one phone call produced a 60 percent reduction in hospitalizations and a 68 percent reduction in emergency room visits within the next 30 days.

“If nobody is coordinating discharged patients’ medication, it’s really a train wreck waiting to happen,” he said.

“You are not your father’s pharmacist,” said Dr. Helling. “You are being trained at the highest level in the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession. Never doubt that you can change the history of our profession.
Adjuvant research exploring new territory

The CU School of Pharmacy is one of 10 health professional schools selected to participate in a national collaborative to address the review, promotion and tenure processes applied to faculty who are engaged in community-based scholarship. Members of the School of Pharmacy’s team include Christopher Turner, associate professor; David Hill, associate dean and associate professor; Catherine Jarvis, PhD; and Heath Turner, assistant professor.

Funded by a three-year $563,842 grant to Community-Campus Partnerships for Health from the U.S. Department of Education’s Fund for the Improvement of Postsecondary Education (PISEB), the group of schools will create templates to show how faculty can be recognized and promoted for community-based scholarship.

“Community-based work is valuable and important, and universities should recognize faculty who want to do work in this area rather than simply categorizing it as service,” said Catherine Jarvis, PhD, assistant dean for Student Services and associate professor at the School of Pharmacy. “This kind of work helps the community, the university and the students, so we shouldn’t be mired in a traditional viewpoint that clinical and laboratory-based scholarship are the primary acceptable criteria for promotion and tenure.”

Historically in academia, in order to be promoted and advance in their careers, members of the faculty are recognized for specific types of research in traditional scientific settings. That research has traditionally been focused in scientific labs or in hospitals and clinics. Healthcare faculty members who have wanted to use their careers to do research in the community have found it more difficult to advance their careers.

“What happens is that this type of good work in the community doesn’t progress unless faculty who are doing it are recognized and promoted for these activities,” said Dr. Jarvis. “There’s value in studying things in a real community that helps with the assessment of a drug or other health care practices beyond just studying them in controlled laboratory settings. We need to know things about the community, about people’s ethnicity and culture and their beliefs about health care.”

Each school in the collaborative has formed a team of faculty and administrators to lead the change process. Members of the School of Pharmacy’s team include Marguerite Childs, associate vice chancellor of Academic Affairs for the CU Health Sciences Center; and pharmacy faculty members Sam Ellis, assistant professor; David Hill, associate dean and associate professor; Catherine Jarvis, PhD; Christopher Turner, associate professor; and Heather Urlich, assistant professor.

At the end of the three-year project, the schools participating in the collaborative will have significantly impacted their promotion and tenure systems to recognize and reward community-engaged scholarship and stimulated similar actions in professional schools across the country.

Other schools participating in the collaborative are Auburn University Harrison School of Pharmacy, Case Western University School of Nursing, Indiana University School of Dentistry, Loma Linda University School of Public Health, University of Cincinnati College of Allied Health Sciences, University of Massachusetts Worcester School of Nursing, University of Minnesota Academic Health Center, University of North Carolina-Chapel Hill School of Dentistry and Vanderbilt University School of Medicine.

SOP participates in national collaborative seeking to change academic culture

Less than a year after her appointment to the Department of Pharmaceutical Sciences, Assistant Professor LaToya Jones, PhD, has landed a one-year $75,000 grant to collaborate with a CU-Boulder researcher to go where few have gone before.

Funded by the Butcher Awards in Biotechnology, Dr. Jones and Dr. Deborah Wurtke, associate professor in chemistry and biochemistry at CU-Boulder will study vaccine antigen/adjuvant interactions. They will look at structural and dynamical changes that occur in proteins that have been adsorbed onto adjuvants using nuclear magnetic resonance (NMR).

“We’re stepping out there into this new territory,” said Dr. Jones. “I do not know of a single publication on this. Even with the research in my lab in general, very few papers have been published looking at the structure and stability of antigens from a biophysical standpoint in the presence of the adjuvant.”

An adjuvant is a substance, given with the antigen, that enhances the response to the injected antigen. A vaccine may work just fine when it’s in the presence of one of the two adjuvants approved for use in the U.S. (aluminum hydroxide and aluminum phosphate), but not so well in the presence of the other. The reason is unknown. By looking at biophysical parameters to detect structural and stability changes, Drs. Jones and Wurtke hope to unravel the mystery of why this occurs. The results of their biophysical study could provide researchers with another tool to screen drug formulations before going into the more expensive and long-term animal studies.

“This grant allows us to come together from different disciplines and different campuses to try to answer the same question,” said Dr. Jones. “It will give us the opportunity to see if our approach is worth pursuing.”

By taking various mutants of a protein adsorbed onto the adjuvant, they will explore how alterations of the conformation and stability of the protein affects the consequences of its interactions with the adjuvant. Dr. Jones will conduct the broader, biophysical characterization of proteins in suspension in her lab and then Dr. Wurtke will use the high field NMR spectrometers at the Boulder campus to provide a detailed picture of how the structure is changed in the presence of the adjuvant. They will also seek to delve into the differences in degradation by proteases of antigen presenting cells.

“The more we understand what’s going on in these systems, the better chance we have of accelerating the development of more efficacious vaccines,” said Dr. Jones.
A study published in the 1998 *Journal of the American Medical Association* reported that more than one million hospital admissions and 100,000 deaths each year are due to severe adverse drug reactions (ADR). This makes ADR the fourth leading cause of death, after cancer, stroke and heart disease.

Because so little is known about these reactions, it is quite difficult to predict which drugs will cause a reaction and which patients will be susceptible. With a five-year RO1 grant of more than $1.4 million, Cynthia Ju, PhD, assistant professor of Pharmaceutical Sciences, hopes to shed light on these life-threatening reactions.

"Due to our limited understanding of the underlying mechanisms, it is impossible to predict which drug candidates will cause immune reactions until thousands of patients start to use the drug during clinical trials or after the drug is released onto the market," she said.

"The earlier we detect these reactions, the better it is for patients and the drug industry.”

It is estimated that 6-10 percent of ADR cases are immune-mediated reactions, which include halothane-induced allergic hepatitis (one in 35,000 with a mortality rate of 40-50 percent), procainamide-induced lupus (one in six) and severe hypersensitivity syndrome induced by a number of drugs, such as carbamazepine, abacavir and nilvadipine. (Halothane is no longer used in adults in Europe and the U.S.)

Carol Balmer, director of the School of Pharmacy's Office of Postgraduate Professional Education, was selected as the 2005 ACPE/AACP Scholar-In-Residence. The Accreditation Council for Pharmacy Education (ACPE) and American Association of Colleges of Pharmacy (AACP) Scholar-In-Residence Program provides an opportunity for pharmacy educators to work with ACPE staff and resources in addressing issues that ACPE and continuing education (CE) providers (whether or not accredited) are working to address. The program, which began in 2004, include providing an opportunity to increase scholarship of individual continuing education providers and assist ACPE in addressing their goals. During the residency, the participant researches and addresses issues of importance to the AACP Continuing Professional Education Section and ACPE.

Dr. Balmer's project involves assessing the learning needs of CE providers in developing skills related to performing scholarly activities and developing educational programming to meet those needs.

Carol Balmer selected as a Scholar-In-Residence

Carol Balmer, PharmD, director of the School of Pharmacy's Office of Postgraduate Professional Education, was selected as the 2005 ACPE/AACP Scholar-In-Residence. The Accreditation Council for Pharmacy Education (ACPE) and American Association of Colleges of Pharmacy (AACP) Scholar-In-Residence Program provides an opportunity for pharmacy educators to work with ACPE staff and resources in addressing issues that ACPE and continuing education (CE) providers (whether or not accredited) are working to address. The program, which began in 2004, include providing an opportunity to increase scholarship of individual continuing education providers and assist ACPE in addressing their goals. During the residency, the participant researches and addresses issues of importance to the AACP Continuing Professional Education Section and ACPE.

Dr. Balmer's project involves assessing the learning needs of CE providers in developing skills related to performing scholarly activities and developing educational programming to meet those needs.

Immune-Mediated Adverse Drug Reaction (IADR) is due to the formation of immunogenic drug protein adducts, however, researchers are puzzled why most people do not show clinical symptoms of IADR. Dr. Ju hopes the five-year National Institute of Health-funded study will reveal the mechanisms of IADR and help identify predisposing factors that determine an individual's susceptibility.

"The central question to understanding this kind of reaction is how drugs in the form of small molecular-weight chemicals cause immune reactions," said Dr. Ju. "Our immune system only recognizes peptides and proteins, not chemicals that small. The hypothesis is that chemically reactive drugs, or more often, reactive metabolites of drugs, bind to endogenous proteins and form immunogenic drug-protein adducts."

It's like poison ivy. When exposed to the urushiol chemical in the sap of poison ivy, an individual develops a poison ivy-induced skin rash. This occurs because the small molecular weight chemical in poison ivy forms a hapten-protein adduct. Haptons are small molecular weight chemicals that by themselves are not immunogenic until they bind with proteins. The hypothesis is that drugs act like haptons.

Dr. Ju and her research team are developing a mouse model of halothane-induced hepatitis. The reason IADR is not well understood is because there is no animal model. The rationale for choosing halothane and mice for the study is four-fold: halothane hepatitis is a four-fold increase of IADR; halothane is used in most studies of IADR; mouse immunological tools are available; and various strains and transgenic mice are available.

"Many research groups have previously tried to develop such a model without success," she said. "We have so far been very pleased with our results."

Early data shows that the adaptive immune system is important. They are investigating the mechanisms involved in immune-mediated liver damage and have come up with a strategy to develop a method to screen the potential of drugs to cause IADR. On average, it costs $800 million to develop a drug. At present, pharmacology and pharmacokinetic/pharmacodynamic issues are much better understood and solutions can be found in most cases. ADR, however, becomes the most significant hindrance to drug development. Pfizer has taken great interest in Dr. Ju's initiative to develop screening methods and decided to fund this project.

Dr. Ju's lab is also investigating the mechanisms of immunological tolerance to drugs. One possible explanation for why only a small percentage of patients are more susceptible to developing IADR is that most people develop immunological tolerance to drug-modified protein antigens as a default mechanism. Understanding what is involved in drug tolerance will lead researchers to identify risk factors.

Previously, her lab found that macrophages in the liver are essential in inducing tolerance to drug protein adducts. Their recent studies revealed that these cells not only act as poor antigen-presenting cells (APC) and fail to induce T cell reaction, but the cells are also capable of actively suppressing T cell activation that is induced by other potent APCs.

Her second NIH grant-funded study focuses on drug-induced severe liver injury, which is the most common cause of withdrawal of drugs from the market. Drug induced liver damage accounts for 25 percent of fulminant liver failure in intensive care units, however, very little is known about the mechanisms involved. Dr. Ju's approach is to use a mouse model of acetaminophen-induced acute inflammatory liver injury. "We found that depletion of macrophages from the liver leads to induced tissue damage, suggesting that these cells are protective," she said. "We hypothesize that the protective effect is through counteracting inflammation and promoting tissue repair. Our ultimate goal is to uncover molecular regulators, which act on these cells and leads to protective effects."
Finding answers through evidence-based medicine

Gone are the days when a search for research data meant going to the nearest medical library to peer at microfiche. Some relevant studies would be found, but the cumbersome process made a comprehensive survey of all available data too time-consuming to be practical.

Evidence-based medicine represents not so much a paradigm shift, but an advancement of the tools used by a clinician, Daniel Friedland, MD, told the standing-room only crowd in Denison Auditorium on April 22. Today's technology dramatically changes how research can be accessed and shared. The Internet makes it possible for pharmacists to find and use research more thoroughly and effectively than ever.

“In large part, the revolution of evidence-based medicine coincides with the development of the Internet,” said Dr. Friedland, president and CEO of Friedland Consulting and assistant clinical professor in the Department of Medicine at the University of California at San Francisco. Dr. Friedland is author of *Evidence-Based Medicine: A Framework for Clinical Practice.*

Evidence-based practice is the process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.

Basing clinical healthcare on research rather than tradition is not a new concept, but it has become more significant as pharmacists have begun looking at patient care procedures through the lens of evidence-based practice.

“Knowing how to blend the rigorous research with clinical experience, expert opinion and understanding of pathophysiology of disease is what is known as clinical expertise,” he said. “To transfer the evidence requires four key skills, expertise, but it’s also about keeping the whole process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.

Basing clinical healthcare on research rather than tradition is not a new concept, but it has become more significant as pharmacists have begun looking at patient care procedures through the lens of evidence-based practice.

“Knowing how to blend the rigorous research with clinical experience, expert opinion and understanding of pathophysiology of disease is what is known as clinical expertise,” he said. “To transfer the evidence requires four key skills, expertise, but it’s also about keeping the whole process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.

Basing clinical healthcare on research rather than tradition is not a new concept, but it has become more significant as pharmacists have begun looking at patient care procedures through the lens of evidence-based practice.

“Knowing how to blend the rigorous research with clinical experience, expert opinion and understanding of pathophysiology of disease is what is known as clinical expertise,” he said. “To transfer the evidence requires four key skills, expertise, but it’s also about keeping the whole process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.

Basing clinical healthcare on research rather than tradition is not a new concept, but it has become more significant as pharmacists have begun looking at patient care procedures through the lens of evidence-based practice.

“Knowing how to blend the rigorous research with clinical experience, expert opinion and understanding of pathophysiology of disease is what is known as clinical expertise,” he said. “To transfer the evidence requires four key skills, expertise, but it’s also about keeping the whole process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.

Basing clinical healthcare on research rather than tradition is not a new concept, but it has become more significant as pharmacists have begun looking at patient care procedures through the lens of evidence-based practice.

“Knowing how to blend the rigorous research with clinical experience, expert opinion and understanding of pathophysiology of disease is what is known as clinical expertise,” he said. “To transfer the evidence requires four key skills, expertise, but it’s also about keeping the whole process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.

Basing clinical healthcare on research rather than tradition is not a new concept, but it has become more significant as pharmacists have begun looking at patient care procedures through the lens of evidence-based practice.

“Knowing how to blend the rigorous research with clinical experience, expert opinion and understanding of pathophysiology of disease is what is known as clinical expertise,” he said. “To transfer the evidence requires four key skills, expertise, but it’s also about keeping the whole process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.

Basing clinical healthcare on research rather than tradition is not a new concept, but it has become more significant as pharmacists have begun looking at patient care procedures through the lens of evidence-based practice.

“Knowing how to blend the rigorous research with clinical experience, expert opinion and understanding of pathophysiology of disease is what is known as clinical expertise,” he said. “To transfer the evidence requires four key skills, expertise, but it’s also about keeping the whole process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.

Basing clinical healthcare on research rather than tradition is not a new concept, but it has become more significant as pharmacists have begun looking at patient care procedures through the lens of evidence-based practice.

“Knowing how to blend the rigorous research with clinical experience, expert opinion and understanding of pathophysiology of disease is what is known as clinical expertise,” he said. “To transfer the evidence requires four key skills, expertise, but it’s also about keeping the whole process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.

Basing clinical healthcare on research rather than tradition is not a new concept, but it has become more significant as pharmacists have begun looking at patient care procedures through the lens of evidence-based practice.

“Knowing how to blend the rigorous research with clinical experience, expert opinion and understanding of pathophysiology of disease is what is known as clinical expertise,” he said. “To transfer the evidence requires four key skills, expertise, but it’s also about keeping the whole process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.

Basing clinical healthcare on research rather than tradition is not a new concept, but it has become more significant as pharmacists have begun looking at patient care procedures through the lens of evidence-based practice.

“Knowing how to blend the rigorous research with clinical experience, expert opinion and understanding of pathophysiology of disease is what is known as clinical expertise,” he said. “To transfer the evidence requires four key skills, expertise, but it’s also about keeping the whole process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.

Basing clinical healthcare on research rather than tradition is not a new concept, but it has become more significant as pharmacists have begun looking at patient care procedures through the lens of evidence-based practice.

“Knowing how to blend the rigorous research with clinical experience, expert opinion and understanding of pathophysiology of disease is what is known as clinical expertise,” he said. “To transfer the evidence requires four key skills, expertise, but it’s also about keeping the whole process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.

Basing clinical healthcare on research rather than tradition is not a new concept, but it has become more significant as pharmacists have begun looking at patient care procedures through the lens of evidence-based practice.

“Knowing how to blend the rigorous research with clinical experience, expert opinion and understanding of pathophysiology of disease is what is known as clinical expertise,” he said. “To transfer the evidence requires four key skills, expertise, but it’s also about keeping the whole process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.

Basing clinical healthcare on research rather than tradition is not a new concept, but it has become more significant as pharmacists have begun looking at patient care procedures through the lens of evidence-based practice.

“Knowing how to blend the rigorous research with clinical experience, expert opinion and understanding of pathophysiology of disease is what is known as clinical expertise,” he said. “To transfer the evidence requires four key skills, expertise, but it’s also about keeping the whole process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.

Basing clinical healthcare on research rather than tradition is not a new concept, but it has become more significant as pharmacists have begun looking at patient care procedures through the lens of evidence-based practice.

“Knowing how to blend the rigorous research with clinical experience, expert opinion and understanding of pathophysiology of disease is what is known as clinical expertise,” he said. “To transfer the evidence requires four key skills, expertise, but it’s also about keeping the whole process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.

Basing clinical healthcare on research rather than tradition is not a new concept, but it has become more significant as pharmacists have begun looking at patient care procedures through the lens of evidence-based practice.

“Knowing how to blend the rigorous research with clinical experience, expert opinion and understanding of pathophysiology of disease is what is known as clinical expertise,” he said. “To transfer the evidence requires four key skills, expertise, but it’s also about keeping the whole process of systematically locating, appraising, and using research findings as the basis for clinical decisions. It emphasizes the use of research and evidence to guide clinical decision making.
Rho Chi President Jennifer Lacoe presided over the initiation banquet held April 19 at Brittany Hill Restaurant. In Dean Diamond’s presentation, “How Do We Know What to Believe,” he discussed the controversial issues surrounding the recent drug withdrawals from the market.

The business portion of the banquet was highlighted by the induction of 25 new Rho Chi members: P2 students - Micheal Andrews, Daniel Bates, Tyler Byassee, Diane Desugny, James Farrar, Sean Fitzpatrick, Kevin Flynn, Dawn Hollingshead, Xiaojun Lu, Monica Manatt, Matthew Marshall, Jessica Meier, Sarah Mercer, Jennifer Meyer, Asad Omar, Stacy Shadburne, Kate Tran, James Vinton and Shaun White; P3 students - Jennifer Cooper, Courtney Frisch, Sara Murphy, Davy To, Thien Tran and Kristen Villalta.

A new executive council for 2005-06 was nominated after the banquet:
- President - Sarah Mercer
- Vice-president - Matthew Marshall
- Secretary - Asad Omar
- Treasurer - Jennifer Meyer
- Historian - Kevin Flynn
- Student council representative - Diane Desugny

Standing from left to right are: Jennifer Meyer, Kristen Villalta, Michael Andrews, Sarah Mercer, Dawn Hollingshead, Matt Marshall, Shaun White, Daniel Bates, Diane Desugny, Ion Ferras, Jessica Meier, Jennifer Cooper, Xiaojun Lu, Monica Manatt, Kate Tran

Front row kneeling are: Tyler Byassee, Kevin Flynn, James Vinton, Stacy Shadburne, Davy To, Sara Murphy, Thien Tran, Sean Fitzpatrick, Asad Omar

Congratulations to Rho Chi inductees & new executive council

School of Pharmacy faculty - active leaders nationally

Thomas Anchordoquy, PhD
Chair-elect, Nucleic Acids Focus Group, American Association of Pharmaceutical Scientists
Finance Committee, American Association of Pharmaceutical Scientists

Jacquelyn Bainbridge, PharmD
Chair, Clinical Neuropharmacy Special Interest Group, American Epilepsy Society
Chair, Programming and Nominations Committee and Research Committee, Central Nervous System Practice and Research Network, American College of Clinical Pharmacy
Board of Directors Advocacy Committee, Epilepsy Foundation of America

Marc Fariss, PhD
Chair-elect, 2004-2005, Toxicology Division, American Society of Pharmacology and Experimental Therapeutics

Douglas Fish, PharmD
President, Society of Infectious Diseases Pharmacists

Laura Hansen, PharmD
Chair-elect, American College of Clinical Pharmacy Women’s Health Practice and Research Network

Brian Hemstreet, PharmD
Chair, 2005, Adult Medicine Practice and Research Network, American College of Clinical Pharmacy
Chair, 2005, Membership Committee, American College of Clinical Pharmacy

Sunny Linnebur, PharmD
Chair, Task Force on Pharmacy and the Elderly, American College of Clinical Pharmacy
Chair-elect, Ambulatory Care Practice and Research Network, American College of Clinical Pharmacy

Tonya Martin
Secretary, Drug Information Practice and Research Network, American College of Clinical Pharmacy

Cindy O’Bryant, PharmD
Chair-elect, 2004-2005, Hematology/Oncology Practice and Research Network, American College of Clinical Pharmacy
Secretary/Treasurer, 2003-2004, Hematology/Oncology Practice and Research Network, American College of Clinical Pharmacy

Joseph Saseen, PharmD
Chair, the American Society of Health-System Pharmacists Commission on Therapeutics

Kathleen Stringer, PharmD
Regent, American College of Clinical Pharmacy

Exit survey responses reveal graduating PharmD students’ plans

We managed a 100 percent return on the surveys. Results tell us:

- 64 percent will reside in Colorado
- 22 percent will enter residency programs
- 62 percent had two or more employment offers
- 78 percent had accepted jobs in their preferred type of practice
- 32 percent will practice in rural and/or underserved areas
- 79 percent will practice in the community/retail field
- 25 percent will practice in hospitals
- 15 percent will practice in settings such as managed care, public health service and home health

Average starting salary for full-time pharmacists who responded - $91,800
Kevin Tripp, RPh

Kevin Tripp is the executive vice president of Drug Operations and president of Drug Store Division for Albertson’s, Inc. As the senior drug executive at Albertson’s, Tripp is responsible for all pharmacy and drug store operations.

A native of Wyoming, Tripp earned his pharmacy degree at The University of Wyoming School of Pharmacy in 1978. He began his career at an Osco store in Casper, Wyoming, as a pharmacist intern and management trainee. He spent nine years in store management as an Osco general manager and unit manager of a combination food and drug store.

Tripp has since held a number of positions in pharmacy operations, regional operations, managed care, pharmacy marketing, advertising and sales. In 1997, he was named to lead the national drug store team and was promoted to his current position in January 2001.

Tripp is cochair for Albertson’s Diversity Leadership Council. He is also an executive board member for the National Association of Chain Drug Stores, and serves on their Leadership Council and Charitable Foundation Committees.

He was instrumental in procuring the Albertson’s Scholarships as well as the Coca-Cola grant for the School of Pharmacy. These awards have since played a significant role in the success of the school’s diversity program.

Tripp works out of Albertson’s Store Support Center in Scottsdale, Ariz. He lives in Scottsdale with his wife and two daughters.

James R. Hertel, BPharm, MBA

Jim Hertel is the publisher of the Arizona and Colorado Managed Care Newsletter, publications of the Denver-based HCIA. For more than 20 years, he has provided the health care industry in Arizona and Colorado with key competitive information and insights on the changing market for health care financing and delivery. His other publications include the Directory of Colorado Managed Care (1985-2003), the Competitive Analysis of the Denver Healthcare Marketplace (1984-2000) and the Arizona Managed Care Directory (1995-2004).

A former HMO executive and development consultant, Hertel spent nearly a decade developing HMO and PPO plans in Colorado, California, Michigan, Ohio and Wisconsin. He helped develop Colorado’s first pharmacy IPA, viz. Denver Area Pharmacy Providers. After graduation from the University of Colorado, he worked as a pharmacist for the Walgreen Company.

Hertel is a frequent public speaker on health care financing issues. His annual State-of-the-State programs in Arizona and Colorado are popular and well attended by healthcare industry leaders.

He is the chairman of the Board of Trustees for the Platte Valley Medical Center in Brighton, past-chairman of the Western Regional (Hospital) Trustees Symposium and a member of the Board of Trustees for the A.J. Kauvar, MD, Foundation.

Hertel has been an active member of the school’s Development Council, connecting the school with knowledgeable health care resources individuals in Colorado for Development Council programs. In addition, he has made significant contributions to discussions by alumni, faculty, staff and donors in developing the vision for the Fitzsimons campus. Hertel has been an articulate and effective advocate and an asset to the school.

Kevin Tripp, RPh, left, and James Hertel, B Pharm, MBA.

**Teaching Awards**

During the School of Pharmacy’s Awards Convocation and commencement activities in May, several faculty received awards for their outstanding contributions to education, research and community health care.

**David C. Thompson**

2005 Chancellor’s Teaching Recognition Award
And P1 Students’ Teacher of the Year

David C. Thompson, PhD, came to the School of Pharmacy as a research associate in 1987. He is now an associate professor of pharmaceutical sciences.

Dr. Thompson also received Teaching Award in 2000 and 2002, and the President’s Excellence in Teaching Award in 1996 and 1997.

A member of several professional organizations, Dr. Thompson has served as a grant reviewer for several organizations, including the National Institutes of Health. He is also a journal referee for nine professional publications, including Life Sciences, Peptides, American Journal of Respiratory and Cellular Molecular Biology and Journal of Clinical Investigation.

He is the author or co-author of four book chapters and dozens of publications and abstracts. His research interests include pulmonary delivery drugs and mechanisms involved in lung cancer development.

Dr. Thompson received both his bachelor’s and doctorate degrees from the University of Melbourne.

**Joseph J. Saseen**

2005 President’s Excellence in Teaching Award
And P2 Students’ Teacher of the Year

Joseph J. Saseen, PharmD, FCCP, BCPS, joined the pharmacy faculty in 1996 as an assistant professor in the Department of Pharmacy Practice. He is now an associate professor of clinical pharmacy and has a joint appointment with the Department of Family Medicine. He is a Board Certified Pharmacotherapy Specialist with Added Qualifications in Cardiology, and is a Fellow of the American College of Clinical Pharmacy.

He received the President’s Award in 1998 and 2002, and the Chancellor’s Teaching Recognition Award in 2003. Dr. Saseen is a member of the American College of Clinical Pharmacy Board of Regents, and is the Chair of the American Society of Health-Systems Pharmacists Commission on Therapeutics.

He received both his bachelor’s and doctor of pharmacy degrees from State University of New York at Buffalo.

**Laura Hansen, PharmD, BCPS**

2005 P3 Students’ Teacher of the Year

Laura Hansen is an assistant professor in the Department of Clinical Pharmacy in the School of Pharmacy and the Department of Family Medicine in the School of Medicine. She joined the faculty in 2000 after several years teaching at Shands University School of Pharmacy.

She earned her BS in pharmacy from the University of Iowa and her PharmD from the University of Colorado in 1997. She then completed a primary care specialty residency with the University of Colorado and Kaiser Permanente.

A member of several school committees, Dr. Hansen belongs to six professional organizations, is a journal referee for seven professional journals and is the author or co-author of more than a dozen articles and abstracts.

The courses she teaches at CU include Family Medicine Specialty Clerkship, Integrated Organ Systems, Pharmacist Based Immunization, Comprehensive Patient Care, Professional Skills Development and Experimental Practice.
Awards and Recognition for exceptional students

PharmD Students
Kappa Epsilon Outstanding Leader Awards
- Debrah Howell
- Kelley Miller

Phi Delta Chi Pharmacy Spirit Award
- Matthew Marshall

Phi Lambda Sigma Leadership Award
- Abraham Wick

Rho Chi Outstanding Student Award
- Jennifer LaCoe

Roche Pharmacy Communications Award
- Richard Blaskovich

School of Pharmacy Clinical Practice Award
- Sunset Andersen

GlaxoSmithKline Patient Care Award
- Jennifer Carnell

Mylan Pharmaceuticals Excellence in Pharmacy Award
- Jeremiah Miller

APHA/ASP Mortar and Pestle Professionalism Award
- Heather Corwin

L.L. Lubin Award
- Holden Community Service Award
- Jennifer LaCoe

The Lefler Book Award
- Richard Blaskovich

The Dean’s Distinguished Student Award
- Parisa Shahmohammadi

Student Council Presidential Award
- Tia Estey

The Lilly Achievement Award
- Michael Long, Edward Paul O’Donnell and Jessica Meier and James Vinton

School of Pharmacy Professional Achievement Awards
- Parisa Shahmohammadi

School of Pharmacy Professional Service Awards
- Michael Long, Edward Paul O’Donnell and Parisa Shahmohammadi

School of Pharmacy Professional Achievement Awards
- P1: Patrina McCauley
- P2: Sarah Merer
- P3: Laura Van Horn
- P4: Nerissa Moore

The Lilly Achievement Award
- Roy Brunson

Student Council Presidential Award
- Nelliana Shaffer

The Dean’s Distinguished Student Award
- Heather Lindell

The Leo Frank Book Award
- Heather Hess

Holden Community Service Award
- Kappa Epsilon

L.L. Lubin Award
- Asian American Pharmacy Students Association

PhD Candidates
David Carbone
- First place - Carl Smith Graduate Student Award for Meritorious Research; Mechanisms Specialty Section of the Society of Toxicology

Tia Estey
- Competitive Travel Award, 2005 Association for Research in Vision and Ophthalmology (ARVO)

Natalie Lassen
- Drug Metabolism and Disposition

Brante Sampey
- Webb-Waring Institute’s Graduate Student Research Award (2005)
- UCHSC Graduate Student Research Forum

Brante Sampey
- Honorable Mention – Carl Smith Graduate Student Award for Meritorious Research;
- Mechanisms Specialty Section of the Society of Toxicology

Student groups recognized for community service
Asian American Pharmacy Students Association
- Members of the Asian American Pharmacy Students Association (AAPSA) received the L.L. Lubin Community Service Award.
- This award was created in memory of Lubin Lutz, a graduate of Capital Pharmacy School in the 1940s. His family, using funds contributed in lieu of flowers at the time of his death in 2002, wanted to provide an award to further diversity through support of students.
- It was suggested that student service projects advancing health care for under-represented groups would give the dollars the greatest impact in the school and community.
- Over its initial two years of existence, the AAPSA’s members have participated in activities to bring health screening information to the community, including the 9News Health Fair, an osteoporosis screening held at a Buddhist temple and providing hypertension and diabetes prevention information to the Vietnamese community.
- In addition, the student members have worked to improve cultural awareness on campus in entertaining ways with food, music and the celebration of the Lunar New Year, also known as the Chinese New Year. The funds from the L.L. Lubin Community Service Award will aid AAPSA in continuing these activities and expanding to provide brown bag counseling sessions.

Kappa Epsilon
- The Kappa Epsilon (KE) chapter of the School of Pharmacy was selected for the second year as the recipient of the Holden Community Service Award. In keeping with the national organization’s focus on breast cancer awareness, chapter members participated in the Komen Race for the Cure.
- On a local scale, members put together baskets of personal items for newly diagnosed breast cancer patients treated at the University of Colorado Cancer Center. KE members continued their involvement with the Grant Street Reach, serving hundreds of meals to homeless and poverty-stricken people in the Denver area, and purchasing clothes and gifts for children and teens of homeless families.
- Two new projects included the Brandon’s House Adopt-A-Room program and a poison prevention program for grade-schoolers. For the Adopt-A-Room program, chapter members chose a design scheme, then purchased decorating materials and painted and decorated one room in a home for battered women and children. The poison prevention program project had KE members bringing second grade students from a neighborhood elementary school to the campus. They taught the children about poison prevention and let them do some role playing as pharmacists, compoundung diaper rash cream and counseling each other in the use of pretend medications.
- The funds from the Holden Community Service Award will enable KE to continue these projects and expand their outreach.
Congratulations, School

Doctor of Pharmacy

Sunset Marie Andersen
Rho Chi
Jamison Mya Armbrester
Jeanette Marie Bates
Ryan James Bickel
Rho Chi, Phi Lambda Sigma
Anthony Robert Blackmore
Andrew Alan Nguyen Brughelli
Edward Philip Burvidas
Yan Cat Cao
Jennifer J. Carnell
Rho Chi, Phi Lambda Sigma
Heather Michele Carwin
Rho Chi, Phi Lambda Sigma
Heather Lynn Caryofilles
Christine Miyun Chung
Rho Chi
Patricia Ann Cochran
Rho Chi
Michelle Jeanette Cortez
Shawndra Lea Cox
Jennifer Ann Dahl
Rho Chi, Phi Lambda Sigma
Tracey Jean Davis
Edwin Villadelo de Guzman
Mercy Delali DeSouza
Phi Lambda Sigma
Helen Doan
Kimberly Elahabi Elalioun
Jennifer Michelle Faccio
Phi Lambda Sigma
Aaron Philip Fallik
Mersieh Faragin
Christopher Jason Fernandez
Heather Frank
Rho Chi
Theresa Esther Garland
Igor Gelman
Hadaya T. Gharibyar
Christopher Scott Habermann
Lien Thuy Hansman
Kristin Anna Henslee
Cassandra Nielsen Herrera
Peter Michael Jaryno
Rachelle Brooke Jaworski
Kevin Michael Johnson
Phi Lambda Sigma
Krystle L Johnson
Jared Reaburn Jones
Jennifer L. LaCoe
Rho Chi, Phi Lambda Sigma
Kathleen Netraya Latanscient
Phi Lambda Sigma
Truc Nguyen Le
Linda Bee Lo
Erik Papaelia Makineni
David Conrad Mc Ewen
Rho Chi
Christa Marie McFadden
Jeremiah Edwin Miller
Rho Chi
Tracey L. Mitchell-Newson
Rho Chi
Nerissa Moore
Rho Chi, Phi Lambda Sigma
Daniel Gustavo Moreno
Stefanie Mew Gin Murdock
Phi Lambda Sigma
Chi Diem Ngo
Bich-Van Thi Nguyen
Ha Thi Bich Nguyen
Rho Chi
Christine Z. Noi
Rho Chi
Laura Beth Nunn
Phi Lambda Sigma
Tracie Sanuki Okimi
Joshua David Oliva
Christine K. Ota
Phi Lambda Sigma
Michelle Marie Pacello
Suzanne Marie Parker
Rho Chi, Phi Lambda Sigma
Julio Eduardo Pazmino
Sonia D. Peterson
Ngoc Cong Pham
Rhonda Lee Polchak
Rho Chi
Sarah Jayne Popish
Brian Scott Ripplinger
Elaine Marie Ripplinger
Rho Chi
Rochelle Christine Romero
Anna Mae Ruivins
Rho Chi, Phi Lambda Sigma
Patricia Padgett Saunders
Heather M. (Lindell) Seashore
Phi Lambda Sigma
Allison Marie Sheldon
Maria Shulga
Jennifer Caroline Steelmon
Shannon Yvonne Stewart
Krista Lynn Stocker
Angie Mohamed Suliman
Stephanie Rose Sumner
Phi Lambda Sigma
Tanya Swarajsorn
Phi Lambda Sigma
Phuoc Hong Than
Aimee Lorraine Thompson
Rho Chi
Rachel Ludia Thompson
Jennifer Lynn Trackwell
Amy Phuong Tran
Huyen Xuan Tran
Amber Victoria Trapp
Melissa Rose Trapp
Kiesha Van Valkenburg
Michelle Barbara Wojtania
Mnymah Aliem Wondim
Melissa Mesler Wong
Jason Loring Worthwood
Amanda Wright
Amber Lee Wyber
Jemal Zenuni
Rho Chi
Heather Lynn Zinner
Phi Lambda Sigma
Shelly Anne Zolnoske

Doctor of Philosophy - Pharmaceutical Sciences

December 2004
Ye Zhang
May 2005
Katherine Anne Peebles
Huiyu Zhou
of Pharmacy Graduates!

Doctor of Pharmacy Non-Traditional Program

December 2004
Christina Dooley
Sudana Squirewell
Jonghee Song Yoo

May 2005
Mark Richard Bishard
Jeanne Furnier
Matthew P. Kern
Susan Elizabeth Mead
Cheryl Ann Quintero
Allyson Welstead Robbins
Lee William Swoboda
Andrew J. Vitt

May 27, 2005
Preceptors: Preparing students to become colleagues

Jacquelyn Bainbridge: 2005 Preceptor of the Year

Associate Professor Jacquelyn "Jacci" Bainbridge, PharmD, was named 2005 Preceptor of the Year by School of Pharmacy students. She also received the award in 2003.

Dr. Bainbridge holds dual appointments in the SOP’s Department of Clinical Pharmacy and the School of Medicine’s Department of Neurology.

She received her BS in pharmacy from Ohio Northern University and graduated in 1995 from the first PharmD class at the University of Colorado. After completing a residency in neurology at CU, she accepted a position with the SOP faculty in 1996.

After graduating, she put together her own specialty residency in neurological pharmacy for her advanced training and she funded it with research dollars she generated. After the residency Dr. Bainbridge then created her faculty position, since there was not a faculty member who specialized in neurology at the time.

She considers the study of neurological pharmacy a pharmaceutical gold mine because it is rich in opportunities. Her neurological specialties include epilepsy, multiple sclerosis, headache and neuroprotection. The drugs in neurological pharmacy are among the leading groups of drugs that cause adverse events, such as a hospital admission.

“This is a problematic group of drugs, because these drugs interact with so many other medications and food,” she said. “You have to think about how the drug works, the mechanism of action, and relate that back to its chemical structure in pharmacology and then use that as a basis for making recommendations about dosing.”

Professor receives nursing leadership award

Ralph Altiere, PhD, professor and associate dean, received the 2005 Dean’s Award for Distinguished Leadership in the School of Nursing (SON). This is a special award that recognizes faculty who have provided exceptionally meritorious service to the school.

Dr. Altiere received this award, according to Patricia Moritz, PhD, RN, FAAN, dean of the School of Nursing, due to his major contributions to the SON through his outstanding and continuous generous service to the school’s Dean’s Review Committee.

“I thank you for your participation, professionalism, commitment of effort and dedicated service to this committee,” wrote Dean Moritz.

“Your input and efforts in the academic reviews were extremely valuable and beneficial to us. Your willingness to participate for many years in this important academic process is very much appreciated.”

Staff recognized for years of service

What was the entire administrative staff of the School of Pharmacy doing in a pool room in the middle of a workday at Coors’ Park in Denver? The occasion was the Staff Recognition Luncheon. If there were doubts about the location, they were erased when the delicious meals were served. The dean and other officers of the school honored the 23 staff members for their years of service. Six of the 23 employees have been with the school more than 10 years. The staff’s combined years of service to the school total 177. The lunch and a later delivery of snack baskets were greatly appreciated by the staff.

SOP Leadership Award

James R. Stephens, III, was selected to receive the School of Pharmacy’s Leadership Award as the outgoing president of the Colorado Pharmacists’ Society. His educational history is a strong statement of his dedication to health care beginning with a BS degree in nursing from the University of Wyoming in 1983.

Stephens followed this with a BS in Pharmacy in 1987, also from Wyoming, and an MBA in Health Care Management in 1997 from the University of Dallas at Irving, Texas. He anticipates graduating from the University of Colorado School of Pharmacy’s Non-Traditional Doctor of Pharmacy degree program in May 2006.

Since 1999, Stephens has been the director of Pharmacy Services at the Platte Valley Medical Center in Brighton, where he started a pharmaceutical care model of practice. His responsibilities include leadership and management of pharmacy services.

He has served as the president of both the Colorado Pharmacists’ Society and the Wyoming Society of Health System Pharmacists and held other officer and board positions in these organizations.
Commitment to research conference showcases students’ work

The Eighth Annual Pharmacy Student Research Conference was opened June 3 by University of Colorado School of Pharmacy Associate Dean Dr. Ralph Altiere, who founded the conference in 1998 with funding from The Merck Company Foundation. The conference offers a unique venue for pharmacy students to present results of their research efforts and to interact professionally and socially with student and faculty colleagues from many other pharmacy schools.

The primary goals of the conference are to promote research among pharmacy students and foster participation in advanced research studies in areas of pharmaceutical science, pharmacy practice, administration, social sciences, outcomes research, or pharmacy education.

The keynote address was delivered Friday evening by Robert MacLaren, BS, PharmD, an assistant professor at the University of Colorado School of Pharmacy. His talk, titled Clinical Research: A Potpourri of Opportunities, provided students with examples of the opportunities that await them in clinical research by expanding on his current research endeavors. Dr. MacLaren’s current research includes evaluation methods to improve the nutritional care of critically ill patients and their access to appropriate use of specific therapeutic agents and a clinical trial to evaluate the immunoprotective effects of the amino acid, glutamine, in liver transplant patients.

On the second day of the conference, 12 podium talks and 36 posters were presented at the School of Pharmacy by students representing 16 U.S. and two Canadian pharmacy schools in the western region. Twenty-three faculty sponsors and other guests from 16 of the represented schools also attended. Presentations were reviewed by two panels of judges comprised of faculty members from the represented schools and awards were given for best podium and poster presentation in the basic sciences and clinical research.

This year’s awardees were:

**Best Science Podium**

CAPSID SCAFFOLD PROCESSING IN HERPES SIMPLEX VIRUS

Raeanna Nerpel and Carlos Enrique Catalano

University of Colorado at Denver and Health Sciences Center, School of Pharmacy, Denver, CO

**Best Science Posters**

THE INFLUENCE OF LIPID EXCIPIENT, CAPRYOL PGMC AND GELUCIRE 44/14 ON P-GLYCOPROTEIN ACTIVITY

Andrea Thamboo, Kristina Sachs-Barrable, Stephen Lee and Kishor M. Wasan

Faculty of Pharmaceutical Sciences, Vancouver, British Columbia

INVOLVEMENT OF RECEPTORS IN THE ACTIONS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA)

Matt Brammer, Debbie L. Gilmore, Jamaluddin Shaikh, Buddy Powe and Rae R. Matsumoto

University of Oklahoma Health Sciences Center, College of Pharmacy, Oklahoma City, OK and University of Mississippi, School of Pharmacy, University, MS

**Best Clinical Podium**

MYCOPHENOLIC ACID EXPOSURE AND GRAFT VS HOST DISEASE IN HEMATOPOIETIC CELL TRANSPLANTATION

Janel Long, Pamela Jacobson, John Rogoshekse, Juliet Barker, Kathleen Green, Juki Ng, Daniel Weisdorf, Ye Tan, Rory Remmel, Ronald Sawchuk and Philip McGlave

Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN

**Best Clinical Poster**

A RETROSPECTIVE DRUG REVIEW OF ALBERTA HEALTH AND WELLNESS DATA: THE PRESCRIBING OF POTENTIALLY INAPPROPRIATE MEDICATIONS TO ALBERTA SENIORS

Colleen Shouldice, Jody Kluchky and Harold Lopatka

Alberta Drug Utilization Program, Edmonton, Alberta, Canada
Knowledge from NTPD program helped ’03 graduate cope with ordeal

For Renee Jahnke, PharmD, the knowledge she gained from the Nontraditional PharmD (NTPD) program not only prepared her for a satisfying career, it helped her family better understand what was ahead when her unborn child needed a new heart.

Dr. Jahnke became pregnant after completing the NTPD program in August 2003. In January 2004, she and her husband learned their unborn son had a rare congenital heart defect called Hypoplastic Left Heart Syndrome in which the left ventricle of the heart didn’t develop. The treatment choice was either a heart transplant or a series of three open heart surgeries which would start when their baby was one week old and end when he was about five.

After many appointments with the perinatologist, pediatric cardiologist, pediatric heart surgeon and the transplant team, the couple decided a heart transplant would be their son’s best hope for a normal life. At 36 weeks of gestation, Baby Boy Jahnke was listed on the heart transplant list. He was first on the list. Had a donor heart become available.

Renee and Mark were given an opportunity to write to the donor family. They went straight to the NICU at Children’s. Noah was born April 14, 2004, at 8 lbs. 14 oz., and was as pink and healthy-looking as any newborn, according to Dr. Jahnke. After she gave Noah a quick kiss, the NICU nurses swept him away and he was put on IV prostaglandin to keep his patent ductus arteriosus (PDA) open and nitrous oxide to regulate lung pressure. A tiny stent was inserted in Noah’s patent ductus arteriosus (PDA) as his own and the team was closing up his chest.

Just after midnight on June 18, 2004, Noah was taken to the operating room where the transplant team of 10 health care professionals opened up his chest and got him ready for the transplant. At 7 a.m. the next morning, a nurse came out to tell the couple that Noah’s new heart was beating vigorously on its own and the team was closing up his chest.

For Renee Jahnke, PharmD, the Nontraditional PharmD (NTPD) program not only prepared her for a satisfying career, it helped her family better understand what was ahead when her unborn child needed a new heart.

Dr. Jahnke became pregnant after completing the NTPD program in August 2003. In January 2004, she and her husband learned their unborn son had a rare congenital heart defect called Hypoplastic Left Heart Syndrome in which the left ventricle of the heart didn’t develop. The treatment choice was either a heart transplant or a series of three open heart surgeries which would start when their baby was one week old and end when he was about five.

After many appointments with the perinatologist, pediatric cardiologist, pediatric heart surgeon and the transplant team, the couple decided a heart transplant would be their son’s best hope for a normal life. At 36 weeks of gestation, Baby Boy Jahnke was listed on the heart transplant list. He was first on the list. Had a donor heart become available, Renee would have had a caesarian section and the transplant would have been performed immediately.

Noah was born April 14, 2004, at 8 lbs. 14 oz., and was as pink and healthy-looking as any newborn, according to Dr. Jahnke. After she gave Noah a quick kiss, the NICU nurses swept him away and he was put on IV prostaglandin to keep his patent ductus arteriosus (PDA) open and nitrous oxide to regulate lung pressure. A tiny stent was inserted in Noah’s patent ductus arteriosus (PDA) as his own and the team was closing up his chest.

Just after midnight on June 18, 2004, Noah was taken to the operating room where the transplant team of 10 health care professionals opened up his chest and got him ready for the transplant. At 7 a.m. the next morning, a nurse came out to tell the couple that Noah’s new heart was beating vigorously on its own and the team was closing up his chest.

The first echocardiogram Noah had after the transplant was so exciting for us,” remembered Dr. Jahnke. “After all those long months of seeing only three chambers functioning, we could now see all four chambers!”

Six days after the transplant Noah went home. He was initially on six medications: cyclosporine, mycophenolate, mycophenolate, nipratin, furosemide, enalapril and gliclazide.

Within a month, Noah was taken off all the medications except the anti-rejection medications. After a month, transplant patients are taken off mycophenolate and switched to azathioprine suspension (compound), as long as there have been no complications or signs of rejection, according to Dr. Jahnke.

There are special medication issues in giving chronic medications to babies. It’s important that the anti-rejection medications be given at the same time every day to keep levels consistent. Babies are not allowed to have pacifiers or bottles for 30 minutes after receiving the cyclosporine, because the medication adheres to the rubber and is not absorbed into the body. And if the babies spit up within 15 minutes of taking the cyclosporine, the full dose must be given again.

Slowly, Noah graduated to once weekly clinic visits, then every other week, and now once a month. He will have a heart catheterization every year and a biopsy will be taken to ensure that there are no signs of rejection. His first heart catheterization is scheduled in July. If everything is normal, the azathio- prime suspension will be discontinued and Noah will only be on the cyclosporine, which he’ll take for the rest of his life.

Noah has developed like any other baby and is expected to live a normal healthy life. He started crawling at six months and took his first steps just before he turned one year old. He can say “mama” and “dada” and jabbers all sorts of other unintelligible words.

Renee and Mark were given an opportunity to write to the donor family who lives in Salt Lake City and the two families are now in regular contact with each other. The donor family’s second daughter, Rielly Nicole, died of SIDS when she was five months old.

“You tell us knowing Noah and knowing how well he is doing has helped them deal with their loss and begin living again,” said Dr. Jahnke. “What a miracle and a blessing our son is!”

A pharmacy supervisor for Kaiser at Hidden Lake Clinic in Denver, Dr. Jahnke continues to work with the NTPD program as a student advisor in the new Credit by Challenge Advisor program.
Scho ol of Pharmacy NEWS

University of Colorado School of Pharmacy Scholarships, May 6, 2005

Annibel Gardner Scholarship

Jennifer Spears

Eryn Roth

Anthony J. Lembach Scholarship

Stacy Shadburne

Burroughs Wellcome Endowment Scholarship

Katey Girard

Chancellor’s Diversity Scholarships

Oluseun Abolaji

Michele Garcia

Daniel Bates

Nancy Hoang

Reannon Castilleja

Debrah Howell

Elena Chemanaeva

Jasmine Le

Jennifer Cooper

Patrina McCauley

Colorado Pharmacist Soci ety Scholarship

Wendy Johnson

Sommer Zarbock

Colorado Pharmacy Foundation Scholarships awarded in honor of Lillian Bird

Wendy Johnson

Sommer Zarbock

Erwin Vincent Scholarship

Duy Tran

Sara Kwon Memorial Scholarship

Kerri Martinez

JM Long Foundation Scholarship

Emilyn Calvera

Jessica Meyer

Ahmed Mudey

Do Quynh Tran

Charli Streig

James L. McDowell Memorial Scholarship

Tasheba West

McKesson Scholarship

Amy Sion

National Association of Chain Drug Stores Scholarship

Michelle Pulido

Southern Colorado Society of Health System Pharmacists Scholarships

Evelyn Phan

Wal-Mart Pharmacy Scholarships

Christian Dobbs

Sean Fitzpatrick

Kaiser Permanentente Kent M. Nelson Scholarships

Richard Blaskovich

Dawson Hollingshead

James Vinton

Raeanna Nerpel

King Soopers Scholarships

Sarah Mercer

Binh Nguyen

Hilda Tanan

Jessica Hoang

Jenny Nguyen

Minh-Thuy Nguyen

Rory Lamberti

Leann Nguyen

Duy Tran

Hung Le

Xuan Nguyen

Thang Van

Stephanie Jones

Rashinlana Patel

Janell Watkins

Francis Macalalag

Jon Peterson

Tuyet-Hong Pham

Shannon Matsko

Dawn Hollingshead

Jill White

Teresa McMahan-Shulkin Memorial Scholarship

Heather Hess

Sueje Park is one of those fortunate indi viduals who was able to turn the passion of her life into her life’s work.

Park is a summer graduate of the School of Pharmacy’s Nontraditional PharmD (NTPD) program, which is a Doctor of Pharmacy degree program offering courses via the internet. In Denver, half a world away from her native country of Korea, she is using her pharmacy knowledge to help in community service and public health education.

“When I make a benefit in another’s person’s life, it makes me happy,” she said. “I have a passion to take care of other people.”

In 1975 Park and her husband immigrated to the United States and both of them joined the U.S. Army in order to continue their education. The couple was stationed at Ft. Riley in Kansas where she worked in finance and administration. After her honorable discharge from the service, Park and her husband and their two small daughters moved to Denver and she enrolled in the School of Pharmacy at CU-Boulder.

During her first year of school, Park commuted by bus to Boulder, but the long hours spent on the road began to take its toll on her. In her second year at CU, Park stayed in a dorm Monday through Friday, going home to her family on weekends. Even her time at home during the weekend became limited while she worked at the Presbyterian Hospital in an internship. After earning her pharmacy degree, she worked as a clinical pharmacist in Denver. Park’s pharmacy career was sidelined in 1994 because of severe, chronic pain from nerve damage caused by pelvic surgery. When pain medication couldn’t relieve her suffering, she turned to alternative therapies such as acupuncture and meditation, which offers her some degree of relief.

“I couldn’t go back to work. I couldn’t do anything, but I wouldn’t give up,” she said. “Not one to let a physical challenge keep her down, Park became an active volunteer and advocate for health care in Denver’s Asian community.

By combining her passion for pharmacy and her desire to be of valuable service to non-English speaking Asians, Park is helping address some of the health care issues in her own community.

In 1995, she began volunteering at the annual 9NEWS Health Fair. A Korean woman who had a screening blood test at one of the fairs looked for Park the following year to thank her. Park had translated into Korean the test results showing abnormal thyroid levels. Because of early detection, the woman’s thyroid cancer was successfully treated.

“When I hear stories like that, I know I can’t quit, even when I get so tired,” said Park. “My husband and daughters are very supportive; that’s how I can continue.”

Due to Park’s efforts, free screenings for hepatitis B are conducted in the Asian community. Out of the 190 Korean and Vietnamese people who participated in the first screening, more than 70 percent tested positive for hepatitis B. From the screening project she began collaborating with a researcher from the School of Nursing on a grant-funded hepatitis B study. She is also working with another researcher on a prostate cancer prevention trial to increase the number of Asian-Americans who participate in and complete the trial.

Because of the SOP’s NTPD online courses and individualized format, Park was able to take classes that fit her schedule. She credits the encouragement of SOP faculty members Carol Balmer, PharmD, and Chris Turner, PhD, for her successful completion of the program and looks forward to continuing her pharmacy work in the Asian community.

“I highly recommend this program to working pharmacists to gain more knowledge and make a difference in their career,” she said.

NTPD online courses a good fit for a busy student.
Class of 1985 celebrates 20-year reunion

On Saturday, May 21, 10 class members and their spouses got together for dinner at Brooklyn’s Restaurant across from the Pepsi Center in Denver to celebrate their 20-year School of Pharmacy reunion. People came from as far away as Michigan and Washington. Friendships were renewed, pharmacy-work war stories were exchanged, and a lot of reminiscing went on.

The food was fine and the company divine. They’re hoping to have an even greater turn out at the next get-together. If you would like to be on the Class of 1985 group email and receive a class directory, please contact kathimillner@comcast.net

Dean Diamond presents lecture at University of Kentucky

Dean Louis Diamond traveled to the University of Kentucky in mid-April to deliver the Swintosky Distinguished Lecture. Annually, an outstanding national or international scientist/educator is invited to the UK College of Pharmacy to present the lecture and to interact with students, faculty and pharmacists. Dr. Diamond’s distinguished career and outstanding reputation in pharmaceutical sciences and pharmacy education were cited as reasons for his being selected to be the 2005 Swintosky lecturer.

The lecture series is named in honor of Dr. Joseph V. Swintosky who served as dean of the UK College of Pharmacy from 1966 until 1986. Under Dean Swintosky’s leadership, the Kentucky college emerged as a world-class institution.

“Flip Flopping Along the Road to Rational Therapeutics” was the title of Dean Diamond’s presentation. It covered the history of radical and hard won advances in scientific and medical knowledge regarding disease causation and treatment. Dean Diamond used several historical examples to demonstrate how reliance on tradition or authority rather than objective scientific evidence can retard medical and therapeutic progress, while at the same time, take a devastating toll on human life and suffering.

After the lecture, Dean Diamond was presented with a plaque and a $1,000 honorarium which he donated to the UK College of Pharmacy’s student fund.

Before assuming his present position, Dean Diamond was on the faculty of the UK College of Pharmacy from 1967 until 1986.

Dean M. Chetkovich, ’63, wrote to tell us he’s officially retired for the second time. His first retirement, after 32 years with Kroger, came in November 2001. The past four years he’s been in independent retail pharmacy in south Texas. His career also included six years of practice before his tenure with Kroger. Chetkovich started at The Apothecary at the University of Colorado at Boulder; followed by U.S. Public Health Service assignments at Shiprock and Crownpoint, New Mexico, and Keams Canyon, Arizona; and finishing with several community pharmacy stints in Denver and then West Virginia.

His experiences ranged from hospital pharmacy, retail, management, IV admixtures, compounding and Hospice pharmacy service. Chetkovich settled in Texas in 1969 and is retired in Seguin, Texas.

James M. Tyler, Jr., ’55, and his wife Helen, who put him through school, sent their regards to classmates in anticipation of a 50th reunion gathering in May. They report good health with a few memory problems and confess that ranch life can get the better of them on occasion. They’d love to hear from school friends and catch up on past years. Feel free to contact them at P.O. Box 1173, Meeker, CO 81641-1173 or 970-878-4822 or jimtioway@amigo.net.

In Memoriam

SOP News received notice that Daniel S. Heffron, III, ’77, passed away on December 20, 2004, in Littleton, Colorado.

Robert Warden, ’50, passed away on May 21, 2005. He was a pharmacist in La Junta and Fort Collins before moving to Granby in 1953. In addition to co-owning Granby Drug, Robert Warden was mayor of Granby and served on the town council and several boards. Shirley and Robert had recently moved to Denver where she remains.

Errata:

We extend our apology to Julia Rawlings for omitting her name from the 2004 donor Honor Roll.

We extend our apology to John A. Biles, ’44, for not including his name in the list of Lifetime Benefactors of the School of Pharmacy beginning in 2003.
## Grants list

<table>
<thead>
<tr>
<th>Grant Title</th>
<th>Institution/Principal Investigator</th>
<th>Catalogue Code</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development of Stable Lyophilized Formulations of Live Attenuated Virus Vaccines</td>
<td>Carpenter</td>
<td>$78,120</td>
<td>7/1/04 — 6/30/05</td>
</tr>
<tr>
<td>Development of Stable Lyophilized Formulations of Live Attenuated Virus Vaccines</td>
<td>Carpenter</td>
<td>$78,120</td>
<td>7/1/04 — 6/30/05</td>
</tr>
<tr>
<td>Antibody Precipitation during Concentration with Tangential Flow Filtration: Salting Out or Non-native Aggregation</td>
<td>Catalano/Maluf</td>
<td>$80,010</td>
<td>2/1/05 — 1/31/06</td>
</tr>
<tr>
<td>Modulation of Adiponection in the Metabolic Syndrome</td>
<td>Catalano</td>
<td>$15,000</td>
<td>7/1/04 — 6/30/05</td>
</tr>
<tr>
<td>A Survey for Evidence Of FNP Inhibition In Subjects From ESS3009</td>
<td>Anderson</td>
<td>$67,421</td>
<td>5/1/05 — 4/30/06</td>
</tr>
<tr>
<td>The Effect of Rosiglitazone on Resistin Levels in Nonobese Diabetic Patients with the Metabolic Syndrome</td>
<td>Anderson</td>
<td>$10,000</td>
<td>12/1/04 — 12/1/05</td>
</tr>
<tr>
<td>The Role fo JNK in Mammary Tumor Development</td>
<td>Van Den Berg</td>
<td>$20,000</td>
<td>2/1/04 — 1/31/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
<tr>
<td>Characterization of caspase-9 resistance in breast cancer cells</td>
<td>Van Den Berg</td>
<td>$108,400</td>
<td>5/1/04 — 4/30/05</td>
</tr>
</tbody>
</table>
Tell us your news

Name

Address City, State and Zip Code

Phone

Email

Spouse also CU alumni? Year?

I'd like my former classmates to know:

Please mail to: School of Pharmacy, 4200 E. Ninth Ave., Mail Stop C-238 Denver, CO 80262

Please email to: SOP.alumni@UCHSC.edu

Also Inside:

- Commencement 2005!
- SOP participates in national collaborative — Page 2
- Dean’s Distinguished Seminar — Page 4
- Graduation Photos — Pages 8-9
- And much more...

School of Pharmacy
Mail Stop C-238
4200 E. Ninth Ave.
Denver, CO 80262

Summer 2005

Nonprofit Organization
U.S. Postage Paid
Boulder, CO